Results 61 to 70 of about 3,750,451 (195)

Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents

Journal of International Medical Research, 2018
Background Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT).
Jimmy T. Efird, Charulata Jindal, Andy C. Kiser, Shahab A. Akhter, Patricia B. Crane, Alan P. Kypson, Aaron L. Sverdlov, Stephen W. Davies, Linda C. Kindell, Ethan J. Anderson   +9 more
doaj   +1 more source

Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents

Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
Despite the substantial clinical success of aspirin and clopidogrel in secondary prevention of ischemic stroke, up to 40% of patients remain resistant to the available antiplatelet treatment.
Monika Marcinkowska, Magdalena Kotańska, Agnieszka Zagórska, Joanna Śniecikowska, Monika Kubacka, Agata Siwek, Adam Bucki, Maciej Pawłowski, Marek Bednarski, Jacek Sapa, Małgorzata Starek, Monika Dąbrowska, Marcin Kołaczkowski   +12 more
doaj   +1 more source

A New Paradigm Shift in Antithrombotic Therapy

Frontiers in Pharmacology, 2013
Decades after the introduction of oral anti-coagulants namely the vitamin K antagonist Warfarin and antiplatelet agents such as Aspirin and Plavix, new classes of direct, small molecule, novel oral anti-coagulant medications and antiplatelet P2Y12 ...
Anita ePudusseri, Raji eShameem, Alex eSpyropoulos   +2 more
doaj   +1 more source

Antiplatelet agents for the treatment of adults with COVID-19. [PDF]

Cochrane Database Syst Rev, 2023
Fischer AL, Messer S, Riera R, Martimbianco ALC, Stegemann M, Estcourt LJ, Weibel S, Monsef I, Andreas M, Pacheco RL, Skoetz N.   +10 more
europepmc   +1 more source

Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis

PLoS ONE, 2015
There is a lack of consensus regarding which type of antiplatelet agent should be used in patients with peripheral arterial disease (PAD) and little is known on the advantages and disadvantages of dual antiplatelet therapy.
K. Katsanos, S. Spiliopoulos, P. Saha, A. Diamantopoulos, N. Karunanithy, M. Krokidis, B. Modarai, D. Karnabatidis   +7 more
semanticscholar   +1 more source

Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review

Pharmacogenomics and Personalized Medicine, 2023
Angelo Oliva,1,2 Davide Cao,1,3 Alessandro Spirito,1 Johny Nicolas,1 Brunna Pileggi,1,4 Karim Kamaleldin,1 Birgit Vogel,1 Roxana Mehran1 1The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY,
Oliva A, Cao D, Spirito A, Nicolas J, Pileggi B, Kamaleldin K, Vogel B, Mehran R   +7 more
doaj  

Antiplatelet agents and anticoagulants for hypertension. [PDF]

Cochrane Database Syst Rev, 2022
Shantsila E, Kozieł-Siołkowska M, Lip GY.   +2 more
europepmc   +1 more source

Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents. [PDF]

Circ Res, 2023
Xu J, Yan N, Wang C, Gao C, Han X, Yang C, Xu J, Wang K, Mitchell MJ, Zhang Y, Nie G.   +10 more
europepmc   +1 more source

Multiple Antiplatelet Therapy in Ischemic Stroke Already on Antiplatelet Agents Based on the Linked Big Data for Stroke. [PDF]

J Korean Med Sci, 2023
Kim TJ, Lee JS, Yoon JS, Park SH, Oh MS, Jung KH, Yu KH, Lee BC, Ko SB, Yoon BW.   +9 more
europepmc   +1 more source

Linking triphenylphosphonium cation to a bicyclic hydroquinone improves their antiplatelet effect via the regulation of mitochondrial function

Redox Biology
Platelets are the critical target for preventing and treating pathological thrombus formation. However, despite current antiplatelet therapy, cardiovascular mortality remains high, and cardiovascular events continue in prescribed patients. In this study,
Diego Méndez, Francisca Tellería, Matías Monroy-Cárdenas, Héctor Montecino-Garrido, Santiago Mansilla, Laura Castro, Andrés Trostchansky, Felipe Muñoz-Córdova, Volker Zickermann, Jonathan Schiller, Sergio Alfaro, Julio Caballero, Ramiro Araya-Maturana, Eduardo Fuentes   +13 more
doaj   +1 more source